The consolidation of nanomedicine

Raphael Zingg, Marius Fischer

Research output: Contribution to journalReview article

Abstract

Over the past two decades, nanomedicine has grown steadily, however, without inducing a palpable shift in the diagnosis and treatment of diseases so far. While this may simply be a consequence of the slow, incremental nature that characterizes many modern technologies, this article posits that there is another set of significant factors harboring explanatory power. Uncertainties concerning safety, regulatory, and ethical requirements may have prompted innovators to stay close to the known and approved, eventually at the cost of innovating in unexplored alleys. Network analysis of all nanomedicine patents in the United States reveals that nanomedicine has indeed rather consolidated than expanded. We detail a set of recommendations that would reduce the uncertainty prevailing in nanomedicine and could contribute to pushing new boundaries. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine.

Original languageEnglish
Article numbere1569
JournalWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Nanomedicine
Medical nanotechnology
Consolidation
Uncertainty
Patents
Electric network analysis
Toxicology
Technology
Safety

Keywords

  • nanomedicine innovation
  • network analysis
  • patent citations
  • regulatory uncertainty

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering

Cite this

The consolidation of nanomedicine. / Zingg, Raphael; Fischer, Marius.

In: Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 01.01.2019.

Research output: Contribution to journalReview article

@article{05413f96c7ce4e66944061f7566e19f3,
title = "The consolidation of nanomedicine",
abstract = "Over the past two decades, nanomedicine has grown steadily, however, without inducing a palpable shift in the diagnosis and treatment of diseases so far. While this may simply be a consequence of the slow, incremental nature that characterizes many modern technologies, this article posits that there is another set of significant factors harboring explanatory power. Uncertainties concerning safety, regulatory, and ethical requirements may have prompted innovators to stay close to the known and approved, eventually at the cost of innovating in unexplored alleys. Network analysis of all nanomedicine patents in the United States reveals that nanomedicine has indeed rather consolidated than expanded. We detail a set of recommendations that would reduce the uncertainty prevailing in nanomedicine and could contribute to pushing new boundaries. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine.",
keywords = "nanomedicine innovation, network analysis, patent citations, regulatory uncertainty",
author = "Raphael Zingg and Marius Fischer",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/wnan.1569",
language = "English",
journal = "Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology",
issn = "1939-0041",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - The consolidation of nanomedicine

AU - Zingg, Raphael

AU - Fischer, Marius

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Over the past two decades, nanomedicine has grown steadily, however, without inducing a palpable shift in the diagnosis and treatment of diseases so far. While this may simply be a consequence of the slow, incremental nature that characterizes many modern technologies, this article posits that there is another set of significant factors harboring explanatory power. Uncertainties concerning safety, regulatory, and ethical requirements may have prompted innovators to stay close to the known and approved, eventually at the cost of innovating in unexplored alleys. Network analysis of all nanomedicine patents in the United States reveals that nanomedicine has indeed rather consolidated than expanded. We detail a set of recommendations that would reduce the uncertainty prevailing in nanomedicine and could contribute to pushing new boundaries. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine.

AB - Over the past two decades, nanomedicine has grown steadily, however, without inducing a palpable shift in the diagnosis and treatment of diseases so far. While this may simply be a consequence of the slow, incremental nature that characterizes many modern technologies, this article posits that there is another set of significant factors harboring explanatory power. Uncertainties concerning safety, regulatory, and ethical requirements may have prompted innovators to stay close to the known and approved, eventually at the cost of innovating in unexplored alleys. Network analysis of all nanomedicine patents in the United States reveals that nanomedicine has indeed rather consolidated than expanded. We detail a set of recommendations that would reduce the uncertainty prevailing in nanomedicine and could contribute to pushing new boundaries. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine.

KW - nanomedicine innovation

KW - network analysis

KW - patent citations

KW - regulatory uncertainty

UR - http://www.scopus.com/inward/record.url?scp=85068214782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068214782&partnerID=8YFLogxK

U2 - 10.1002/wnan.1569

DO - 10.1002/wnan.1569

M3 - Review article

AN - SCOPUS:85068214782

JO - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

JF - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

SN - 1939-0041

M1 - e1569

ER -